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Abstract
Background: Transaldolase deficiency (TALDO-D) is a rare autosomal recessive
inborn error of the pentose phosphate pathway. Since its first description in 2001,
several case reports have been published, but there has been no comprehensive
overview of phenotype, genotype, and phenotype–genotype correlation.
Methods: We performed a retrospective questionnaire and literature study of clinical,
biochemical, and molecular data of 34 patients from 25 families with proven TALDO-
D. In some patients, endocrine abnormalities have been found. To further evaluate
these abnormalities, we performed biochemical investigations on blood of 14 patients.
Results and conclusions: Most patients (n = 22) had an early-onset presentation
(prenatally or before 1 month of age); 12 patients had a late-onset presentation
(3 months to 9 years). Main presenting symptoms were intrauterine growth restric-
tion, dysmorphic facial features, congenital heart disease, anemia, thrombocytope-
nia, and hepato(spleno)megaly. An older sib of two affected patients was
asymptomatic until the age of 9 years, and only after molecular diagnosis was
hepatomegaly noted. In some patients, there was gonadal dysfunction with low
levels of testosterone and secondary luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) abnormalities later in life. This overview provides
information that can be helpful for managing patients and counseling families
regarding prognosis. Diagnostic guidelines, possible genotype–phenotype correla-
tions, treatment options, and pathophysiological disease mechanisms are proposed.
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1 | INTRODUCTION
Transaldolase deficiency (TALDO-D, Eyaid syndrome,
OMIM 606003) is a rare autosomal recessive inborn error of
the pentose phosphate pathway first described in 2001.1
Patients can present either prenatally, with intrauterine
growth restriction (IUGR) and/or oligohydramnios; in the
neonatal period, with dysmorphic facial features, cardiovas-
cular defects, and hepato(spleno)megaly; or later in life, with
a milder phenotype or even no symptoms (one patient
described so far). To perform a systematic review of clinical
and biochemical findings in patients with TALDO-D, ques-
tionnaires were sent to nine physicians of patients with
proven TALDO-D, and a literature review was performed.
In some patients, endocrine abnormalities (e.g., abnormal
genitalia, vitamin D deficiency, hypergonadotrophic hypo-
gonadism) have been reported,1–3 (M.F. Mulder, personal
communication). To further evaluate endocrine characteris-
tics, we performed endocrine investigations in blood sam-
ples from 14 living patients. Here we present an overview of
the clinical spectrum of TALDO-D with clinical, biochemi-
cal, and molecular genetic data of a cohort of 34 patients
from 25 families.
2 | METHODS
2.1 | Collection of clinical and
biochemical data
The VU University Medical Center (VUMC), Amsterdam,
was the first center to diagnose a patient with TALDO-D.
Since then, diagnoses have been made on patients from all
over the world using biochemical and molecular diagnostics.
Until 2015, a pathogenic mutation or an enzymatic deficiency
was identified in 19 patients, and comprehensive question-
naires evaluating clinical and laboratory findings in TALDO-
D were sent to physicians of these patients and their affected
siblings. Additionally, all patients with published case reports
until 2015 were included. This study was approved by the
ethics committee of the VU University Medical Center,
Amsterdam, The Netherlands, No 2012/426.
2.2 | Biochemical studies
Sugars and polyols were measured in urine and/or plasma by
gas chromatography (GC)4; the seven-carbon sugars were
measured using liquid chromatography tandem mass spec-
trometry (LC-MS/MS).5
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2.3 | TALDO enzyme analysis
In cell extracts (fibroblasts, lymphoblasts, liver) from
13 patients, TALDO activity was measured either using LC-
MS/MS1 or spectrophotometrically.6
2.4 | Analysis of the TALDO1 gene
Mutation analysis of the TALDO1 gene (GenBank Acces-
sion No. L1943.2) was performed by direct sequence analy-
sis of genomic DNA from blood.1
2.5 | Analysis of endocrine function
To obtain information about endocrine manifestations in
TALDO-D patients, measurements were performed on fast-
ing serum and ethylenediaminetetraacetate (EDTA) plasma
of 14 patients (11 male/3 female, median age 7 years, range
2–16 years) with TALDO-D. Fasting serum insulin and cor-
tisol were measured using an automated immunoassay
(Centaur, Siemens Diagnostics). Follicle-stimulating hor-
mone (FSH), luteinizing hormone (LH), and testosterone
were measured using another automated immunoassay
(Architect, Abbott Diagnostics). Testosterone was measured
using the second-generation assay.7 Thyroid stimulating hor-
mone (TSH) and free T4 were measured in serum using an
automated immunoassay (Cobas, Roche Diagnostics). Cho-
lesterol, glucose, and anti-Müllerian hormone (AMH) were
measured in serum using the Cobas (Roche Diagnostics). In
EDTA plasma, adrenocorticotropic hormone (ACTH) was
measured using an automated immunoassay (Liaison, Dia-
sorin). Estradiol and 17-hydroxyprogesterone were mea-
sured in serum using manual competitive immunoassays
(Delfia, Perkin Elmer and DRG Instruments, respectively).
In serum, using an in-house LC-MS/MS method,
androstenedione,8,9 25-OH vitamin D10 and dehydroepian-
drosterone sulphate (DHEAS)11 were measured.
3 | RESULTS
3.1 | Patients
Completed questionnaires on 25 patients from 15 families
were received. For nine additional patients from whom no
questionnaire data were available, data were collected from
publications.2,3,12–14 Thirty-four patients from 21 families
were included [23 male and 11 female, median age at last
visit or at death 6 years (varying from 0 to 25 years, n = 33
(one unknown))] Only one patient reached adulthood; she




Patients came from 21 different families of Middle Eastern
[Saudi Arabia, belonging to two tribes that claim a common
ancestor6 (n = 6)], Asian (n = 5), western Asian/southeast
European (Turkey) (n = 4), European (n = 4), West African
(n = 1), and unknown (n = 1) origin. In six families, more
than one child had TALDO-D. In 16 families, there were
one to ten unaffected children (n = 55): 38% of children
born in these families were affected with TALDO-D; 81% of
parents were consanguineous (17 of 21 families).
Age at presentation
Patients came for medical attention prenatally or between
birth and 9 years of age (n = 33; one was unknown; mean








Anemiaa 77 75 76
Thrombocytopeniaa 77 67 74
Hepatomegalya 77 100 85
Splenomegalya 45 25 38
Pancytopenia 5 33 15




Cardiac abnormalitiesa 68 50 62




Triangular faciesa 41 33 38
Tubulopathy 32 25 29
















Hypotoniaa 27 8 21
IUGR, intrauterine growth restriction.
aFeature of presentation.
bNot able to determine in the younger children.
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0.44 year). Twenty-two (64.7%) patients presented prena-
tally or up to 1 month after birth (early presentation). Late
presentation (> 3 months of age) was seen in 12. One
asymptomatic patient was diagnosed at the age of 9 years
due to family screening (F13-P1). Clinical symptoms are
shown in Table 1.
Prenatal manifestations
In two cases the mother of the affected children presented
with excessive weight gain during pregnancy, hydropic pla-
centa, and oligohydramnios (n = 2; F05-P1 and F05-P2).
One of these children showed generalized edema. IUGR was
seen in seven early-onset patients (32%) and reported in
another two cases of late presentation (17%). Fetal hydrops
was seen in four patients and neonatal edema in seven.
Physical examination (dysmorphic features, growth)
Dysmorphic features were observed in 50% of patients with
TALDO-D. The most prominent features were skin abnor-
malities (68%), triangular-shaped face (38%), low-set ears
(35%), wide mouth (26%), and thin lips (24%) (n = 32;
2 unknown). Postnatal growth was reported normal in 14/22
patients with early presentation. In late-onset presentation,
growth was within the normal range in 10/12 patients
(1 unknown). In total, at least 24/34 (71%) had a normal
growth. Head circumference was normal in 15 and not
reported in 19. Reports of low body mass index (BMI)
and/or short stature in the course of the disease were men-
tioned in the other nine (26%) patients.
Skin
Cutis laxa/wrinkled skin was seen in more than half of the
patients (n = 18, 53%), and capillary hemangioma in six
(18%). This feature may attenuate and disappear as patients
grow older. In 12 patients from six families, thin pigmented
skin was seen on distal metacarpal joints (knuckles).
Cardiac abnormalities
Congenital heart defects, such as ventricular septal defect
(VSD) and/or atrium septal defect (ASD), occurred in
12 (35%) cases. Bicuspid aortic valve (n = 2; F01-P1;
F21-P1), aortic coarctation (n = 1; F01P1), and dextrocardia
(n = 1;F09P2) were observed. Patent foramen ovale and
persistent ductus arteriosus were seen in 11 patients (32%).
Cardiac abnormalities were found in similar numbers in
early- and late-onset cases. Cardiomyopathy was present in
three (F02-P1; F18-P1; F21-P1) patients (9%), hypertrophy
of the left and or right ventricle occurred in four (F02-P1;
F03-P4; F18-P1; F17-P1) (12%), and possible secondary
abnormalities [tricuspid regurgitation (TR), valve prolapse]
were found in two (6%).
Hepatic evaluation
Hepatomegaly was observed in 77% of patients when pre-
sentation was early and 100% when presentation was late. In
50% of cases, hepatomegaly coincided with splenomegaly in
both early and late presentation. Hepatic dysfunction was
found in 17 of the 22 cases (77%) who presented early and
was associated with fibrosis and cirrhosis in 23% and 18%,
respectively. Decreased hepatic synthetic function was nota-
ble (decreased serum albumin and abnormal clotting factors)
in 53% patients; aspartate aminotransferase (AST) and/or
alanine aminotransferase (ALT) were elevated in 10/22
(59%) and bilirubin in 8/22 (36%). In 9/22 patients (41%),
hepatic dysfunction was progressive (n = 2 stable,
11 unknown).; hepatic dysfunction was present in 10/12
cases (83%) when presentation was late [AST and/or ALT
elevated in 7/12 (58%) and bilirubin elevated in 3/12 (25%)]
and was associated with cirrhosis in 25%. Liver biopsy was
done in 16/34 patients; fibrosis and/or cirrhosis were seen in
14. Mild steatosis was observed in 4/16 patients. No signs of
inflammation or storage of copper, iron, or glycogen were
reported. Two patients received liver transplants for progres-
sive liver dysfunction or development of hepatocellular
carcinoma.
Alpha fetoprotein (AFP) levels were determined in
20 patients; levels were within the normal range in three
patients (<3.9 to <8 ng/ml). In the 17 patients with increased
levels, these ranged from 4 to 64,959 ng/ml (mean
8075 ng/ml; median 198 ng/ml). Follow-up of AFP levels
was done in 15 patients; most showed a decrease, normaliza-
tion occurred in three (one after liver transplantation), and
stabilization was seen in three.
Hematological features: blood cell count
Anemia was seen in 17/22 (77%) of early-presentation cases.
The range of lowest hemoglobin levels reported was
52–112 g/L, with a median of 80 g/L (3.2–6.9 mmol/L,
median 4.9 mmol/L). Values were normal in four patients.
In late-onset presentation, anemia occurred in a similar per-
centage (75%). Mean corpuscular volume ranged from 66.6
to 103 fl, with a median of 89.6 fl (normal: newborn:
95–120, child: 70–95; adult: 82–98); two patients were
below the normal range. Ferritin levels were measured in
14 cases, seven of which showed normal levels. In three
patients, levels were elevated up to 2347 μg/L (ref
21.8–274.6): in two of these patients, levels were only above
normal in a period of hemolytic anemia, and a mild decrease
was seen in four patients. Thrombocytopenia was a promi-
nent feature and was seen in 77% and 67% of patients in
early and late presentation, respectively. Median platelet
count was 48 (early onset) and 53 (late onset) × 109/L.
Follow-up of thrombocyte count was known in 26 and
values were given in 11. Thrombocyte values were
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fluctuating or stable in most patients. In 3/26 patients (with
information given with respect to thrombocytopenia), throm-
bocytopenia resolved; in one of these patients, this occurred
after liver transplantation. Thrombocyte values decreased in
two patients. White blood cell number was depressed in
5/34 patients (15%) (pancytopenia was mentioned in
5 patients). This was observed later in the disease course in
all five cases.
Renal manifestations
Proximal and distal tubular dysfunction (aminoaciduria, pro-
teinuria, and loss of electrolytes) was the most prominent
renal feature in TALDO-D (10/34, 29%). Glomerular prob-
lems occurred but were not frequently reported. Renal stones
developed in 4/34 (12%) cases. Renal ultrasound (US) was
abnormal in eight patients: hydronephrosis in six, nephrome-
galy in one, echogenic foci at the tips of the renal pyramids
in one, and hypoplastic right kidney in another. In
16 patients, no abnormalities were detected on ultrasound
(US). For the other ten patients, renal US was either not per-
formed or no information was given.
Additional, less-frequently observed, features
Additional unique observations in single patients were
ichthyosis, gallstones, and high iron content in hepatocytes
and thyroid cells on histology associated with elevated iron
and serum and liver ferritin (F03-P2). One sibling also had
high iron levels (F03-P4), but no information on tissue iron
was available. Nystagmus and pituitary microadenoma were
observed in a single patient.
Development and neurological symptoms
Development was normal in most (18/25, 72%) patients.
Some experienced (mild) motor delay (n = 7). No informa-
tion on development was given for nine patients. Normal
visual and auditory development was noted in 29 patients,
with no information in three. Abnormalities were seen in
two patients [horizontal nystagmus (F16-P2) and sensorineu-
ral deafness (F04-P1)]. Six of 34 patients displayed muscular
hypotonia at disease onset (18%).
3.1.2 | Endocrine evaluation
Gonadal function
In 11/34 patients (32%), abnormal external genitalia were
present at birth (3 males with small phallus, 3 females with
clitoromegaly, 6 males with cryptorchidism). In six patients,
hypergonadotropic hypogonadism was reported, including
in a 16-year-old male patient with elevated LH and FSH
levels and normal serum testosterone. Al-Shamsi et al.
described a 25-year-old female patient with secondary
amenorrhea from the age of 23, high prolactin levels, and a
pituitary microadenoma.12
Gonadotrophin levels were assessed in 14 patients. Tan-
ner stage was not available in most patients; however, eight
were <7 years and presumed prepubertal. In two patients
[girl 9 years (Tanner stage unknown) and boy 14 years
(Tanner stage 4–5)] elevated gonadotrophin levels with low
serum testosterone were found; this was not reported in the
questionnaire of the 9-year-old girl. In the 16-year-old
patient reported to have elevated gonadotrophins, we mea-
sured mildly elevated FSH (16.7 U/L) and normal LH
(7.2 U/L) and testosterone (13.4 nmol/L), indicating a nor-
mal Leydig cell function and a compromised Sertoli cell
function. A female patient of 2.5 years had increased LH
and FSH levels and a low serum AMH, indicating ovarian
failure.
Adrenal function
DHEAS, the sulfonated product of DHEA, is mainly pro-
duced in the adrenals and was measured in 14 patients. It
was decreased in a 16-year-old male patient who also had
low androstenedione (a DHEA product). In one patient
(female 2.3 years), we measured a mildly elevated
17-hydroxyprogesterone (17-OHP) (10 nmol/L; n 1.5-6.4).
ACTH and basic cortisol levels were normal in all
14 patients. In 5/14 (36%) patients, there were abnormalities
concerning development and function of adrenals and
gonads.
Thyroid function
TSH and free T4 were normal in 11/13 investigated patients.
One patient was diagnosed with primary hypothyroidism
[free T4 7.1 pmol/L (9–19 mol/L); TSH 327 mU/L
(0.35–4.94 mU/L)]. She was treated with levothyroxine.
When we measured her thyroid function, free T4 was nor-
malized (15.3 pmol/L; controls 12–22 pmol/L), although
TSH level remained elevated (112 mU/L; controls 0.6–4.8
mU/L). A recent assessment showed a normal thyroid func-
tion with levothyroxine: free T4 18.3 pmol/L (9–19 mol/L);
TSH 5.26 mU/L (0.35–4.94 mU/L). One patient had a
mildly increased TSH value (8.3 mU/L; controls 0.7–6.0
mU/L) with a normal free T4 (14.9 pmol/L; ref. 12.3–22.8
pmol/L), which was considered as subclinical hypothyroid-
ism. One patient was known to have transient
hypothyroidism.
Growth
Abnormalities concerning growth and bone features that
were described in a minority of patients were: (1) Short
stature, with a concomitant insulin-like growth factor-1
(IGF-1) deficiency, was identified in 2/34 patients. One
patient received growth hormone treatment with poor
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growth response; no further information was given or anal-
ysis performed on the remaining patients. (2) Bone abnor-
malities where seen in 4/34 patients: In three decreased
bone density (osteopenia) of a varying degree was
observed. One patient presented with rickets caused by
vitamin D deficiency, possibly related to tubulopathy. In
the fourth patient, increased densities of long-bone meta-
physes and skull and histological findings on bone biopsy
suggested osteopetrosis.
3.1.3 | Other endocrine functions
Glucose homeostasis
In this cohort of 34 patients, one was known to experience
neonatal hyperinsulinism. Insulin was elevated in 2/14 blood
samples taken during fasting and was not associated with
hypoglycemia. Presumably, the patient had not fasted
completely. Fasting glucose was normal in all but one
patient (2.2 mmol/L), who was not known to have clinical
hypoglycemia and had normal insulin levels.
Vitamin D measurement
25-OH vitamin D was >40 nmol/L in all 14 patients and
>50 nmol/L (target value) in 12/14 patients. Five of
13 patients received vitamin D supplementation; supplemen-
tation in one patient was unknown.
3.1.4 | Clinical course
Survival
Of the 34 patients, eight (24%) died at a median age of 2.3
(0–17) years. One pregnancy was terminated because of
multiple malformations (heart, liver, kidney) at 28 weeks of
gestation. Six patients had a neonatal onset, with presenta-
tion in the first week. One patient had his first symptoms at
3 months. Of these seven patients, six died within 6 months
due to liver failure; the other patient died at 17 years from
acute massive intra-abdominal bleeding during decompen-
sated liver cirrhosis with portal hypertension and oesopha-
geal varices.
Main features during the clinical course
were hepatomegaly with increased ALT/AST, increased bili-
rubin levels, cholestasis, and liver dysfunction resulting in
coagulopathy and/or bleeding. Development of hepatocellu-
lar carcinoma was observed in one patient, leading to liver
transplantation. Susceptibility to infections was also reported
(n = 5). Renal findings included tubulopathy in three and
renal failure in two. Hematological abnormalities reported
were thrombocytopenia (n = 11) with associated anemia in
seven. Pancytopenia was observed in five patients during
follow-up.
3.1.5 | Laboratory diagnosis
Patients were detected by urinary, plasma, enzymatic, or
DNA investigations. The diagnosis was confirmed by DNA
analysis of the TALDO1 gene in all 34 patients.
Biochemical analysis
Polyol analysis was performed in urine, plasma, and cerebral
spinal fluid (CSF) in 27, 11, and one patient, respectively. In
all 27 patients, abnormal polyols and/or seven-carbon sugars
were detected in urine: increased excretion of erythritol, ara-
bitol, ribitol, sedoheptitol, perseitol, sedoheptulose, manno-
heptulose, and sedoheptulose-7P. In older patients
(>9 years), erythritol and arabitol are sometimes within the
reference range. In 11 patients, plasma investigations were
performed and showed mild elevations of erythritol, arabitol,
and ribitol. In one patient, polyols in CSF were measured
and showed a mild elevation of ribitol (19 μmol/L; reference
values <6), while concentrations of erythritol and arabitol
were normal. Erythronic acid was elevated in three patients
and not mentioned in the others. Erythronic acid has been
previously detected as a biomarker in TALDO-D.15
Other biochemical abnormalities included reduced activi-
ties of complex I–IV in muscle and liver in one and
increased excretion of 2-ketoglutaric acid and fumaric acid
in three patients. Lactate was normal in 11 patients, while
elevated initially after birth in one, during exercise in one,
and during the terminal phase in one. Amino acid analysis in
urine and plasma was normal in one and eight patients,
respectively. Aminoaciduria was seen in six patients; four
patients had a typical amino acid pattern in plasma associ-
ated with liver dysfunction with high glutamine, methionine,
and ethanolamine levels. For the other patients no informa-
tion was given on amino acids in urine and plasma.
Enzymatic analysis
TALDO enzyme deficiencies were measured in 13 patients
(38%, 8 in fibroblasts, 4 in lymphoblasts, 1 in fetal liver).
Residual activity when measured by spectrophotometry was
<6% of controls.
Genotype
Most patients (94%) were homozygous for a mutation in
TALDO1 (Genbank # NM_006755; gi5803186), which is in
line with the high frequency of consanguinity. Different
types of mutations have been detected, including missense
mutations, in frame deletions, and frameshift mutations. In
our group, 11 different mutations were identified (see Sup-
plemental Table 1). The most frequent mutations were
c.793delC; p.Gln265ArgfsX56, present in 12 patients (35%)
from the same ethnic background (Middle East);
c.512-514delCCT; p.Ser171del in five patients (15%); and
c.574C > T; p.Arg192Cys in five patients (15%).
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Genotype–phenotype correlation
There is no clear genotype–phenotype correlation. All five
patients from two families with the homozygous
c.512_514delCCT; p.Ser171del mutation presented intra-
uterine or neonatally, while all three patients from one fam-
ily with the homozygous c.512C > T; p.Ser171Phe
mutation had a late-onset presentation.
3.1.6 | Treatment
In general, patients should receive standard symptomatic
care, e.g., optimal nutrition and vitamin supplementation for
the presenting symptoms (liver and renal) and transfusion
support and monitoring for bleeding and thrombocytopenia.
A single specific experimental therapy for TALDO-D
patients has been recently reported using an oral glutathione
precursor, N-acetylcysteine (NAC), over a 6-month period,
which was well tolerated and was associated with a sus-
tained normalization of alpha fetoprotein (AFP) levels and
stable clinical course.
Two patients from our group of 34 (F13-P3; F17-P1) and
one additional patient (V. Valayannopoulos, personal com-
munication) underwent liver transplantation. The first two
patients presented progressive liver dysfunction, and patient
F13P3 had cirrhosis and hepatocellular carcinoma. Both
were successfully transplanted at the age of 1 year, before
the diagnosis was known. Both patients were stable at the
age of 7 and 3 years, respectively, with normal blood count
and normal or mildly elevated liver enzymes the other
patient (V. Valayannopoulos, personal communication) died
in the course of a liver transplantation. This patient received
an orthotopic liver transplant from a cadaveric donor at
5 months of age. Transplantation was marked by portal
thrombosis at day 3 posttransplant that required a new surgi-
cal procedure and was associated with a partial splenectomy.
The postsurgical course was marked by pulmonary infection
leading to respiratory distress and eventually death in the
second week posttransplant. This patient had received anti-




We report the largest series to date of TALDO-D patients:
34 patients from 25 families. Core clinical features in this
patient group include developmental abnormalities of the
heart, skin, kidney, and abnormal external genitalia at birth,
with the two most important findings being liver and hema-
tological involvement. TALDO-D is mainly a nonneurologi-
cal disease, and cognition was normal in most patients.
Delay in motor development, observed in some patients,
was thought to be due to hypotonia (21%) and hyperlaxity
(6%). Patients with a neonatal presentation within the first
week of life seemed to have a worse prognosis, with 27%
mortality within the first 6 months of life, most likely due to
severe liver failure. Most of these patients showed the typi-
cal dysmorphic and congenital abnormalities of TALDO-D,
as described in Table 1.
4.1.1 | Hepatic abnormalities
The liver is the most frequently affected organ, seen in
>85% of patients, and is where TALDO enzyme activity is
highest and thus where the greatest impact can be expected.
This results in liver dysfunction and damage, leading to life-
compromising complications (cirrhosis, liver failure, devel-
opment of malignancy).
4.1.2 | Hematology–splenomegaly
Splenomegaly is a frequent finding (45%) in patients with
early disease onset. Of these patients, about half (23%) also
show thrombocytopenia. An enlarged spleen could be
caused by extramedullary (fetal) hematopoiesis, portal
hypertension, and cirrhosis and can result in severe thrombo-
cytopenia. Thrombocytopenia, however, is a prominent fea-
ture of TALDO-D throughout life but can also be present in
patients without splenomegaly (n = 1). This indicates
splenomegaly might be secondary to splenic tissue hyperpla-
sia, liver cirrhosis, and portal hypertension.16
Anemia was seen even more frequently, presenting in
77% of patients in the neonatal period and late presentation
in 75%. Mean corpuscular volume (MCV) did not seem to
change with time, and there was no indication of iron, folic
acid, or vitamin B12 deficiency. Possible causes for anemia
can be hemolysis [as is seen in glucose-6-phosphate dehy-
drogenase (G6PDH) deficiency due to low reduced nicotin-
amide adenine dinucleotide phosphate (NADPH)],
decreased hematopoiesis in fetal liver and/or spleen, bleed-
ings, failure to regenerate, or renal dysfunction
(no information on markers for decreased bone marrow
activity, lack of erythropoietin or function, on lactate dehy-
drogenase (LDH) levels or haptoglobin were available). As
there were no data on reticulocyte counts, we were unable to
determine whether the anemia was regenerative or not.
Fetal hydrops and placental edema might be related to
anemia or could be caused by accumulating polyols during
fetal development, which may lead to an osmotic disequilib-
rium, which is responsible for water movements through the
different fetal fluid compartments.17,18
Abnormal skin, described as cutis laxa/wrinkled skin,
which is seen in more than half of the patients, might be
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caused by fetal edema of the skin, which disappears toward
the end of pregnancy when fetal renal function increases.
Cardiac abnormalities, i.e., developmental disorders,
were seen in about a third of patients. This high percentage
must be at least partly due to TALDO-D; however, patho-
genic etiology remains unclear. Dextrocardia, seen in one
patient, could indicate the importance of the TALDO1 gene
in early fetal development. Cardiomyopathy and/or ventricu-
lar hypertrophy could be secondary problems (ASD, VSD).
Prolapse and valvular insufficiency could be secondary to
cardiac malformations; this needs further study and can be
pursued at the occasion of cardiac surgery.
4.1.3 | Endocrine
Hypergonadotropic hypogonadism is a relatively frequent
finding present in 7/34 patients (21%). This reflects gonadal
dysfunction and in some cases infertility. Measurement of
LH and FSH is indicated in children in the pubertal age. If
hypergonadotropic hypogonadism is found, treatment with
sex hormones is indicated to induce puberty. Because of the
observed microphallus, cryptorchidism, and clitoromegaly in
some patients, a developmental or hormonal abnormality
with developmental consequences cannot be ruled out. No
pregnancies have been reported in patients with TALDO-D,
but the patient group is also young, with only one adult
patient of 25 years old. Possibly, secondary effects resulting
in further endocrine symptoms, such as effects on bone and
mineral metabolism, could be due to renal loss of proteins or
minerals. Decreased production of DHEAS and hormone-
binding proteins could be due to reduced protein synthesis
from a damaged liver and could lead to ongoing hormonal
disturbances. The NADPH/NADP ratio that plays a role in
most hormone biosynthetic pathways, and the decreased
NADPH in TALDO-D could be a cause for the abnormal
steroid hormone production,19 Single TALDO-D cases have
been associated with hyperinsulinism, transient hypothyroid-
ism, or vitamin D deficiency, and other causes outside
TALDO-D may be considered.
Short stature and or decreased body mass index (BMI)
was described in nine patients in our cohort, of whom two
had IGF-1 deficiency. We speculate that the IGF-I defi-
ciency in one patient was related to delayed puberty due to
hypergonadotropic hypogonadism. In the other patient, poor
nutrition might have caused the decreased IGF-I. Cardiac or
renal problems and the effect of a chronic disease can further
contribute to poor growth in some patients. Clinical course
ranges from asymptomatic to very severe, with hepatic fail-
ure leading to early death. In some patients, clinical symp-
toms have been reported to improve over time, including
liver manifestations.2
4.2 | Diagnosis
Any patient presenting with hepato(spleno)megaly and dys-
morphic features associated with skin abnormalities (cutis lax-
a/wrinkled skin), liver dysfunction (cholestasis, elevated
transaminases, coagulopathy), anemia, and/or thrombocytope-
nia should be investigated for TALDO-D. As not all patients
have cutis laxa or splenomegaly—and probably only the most
severely affected patients are currently recognized—patients
without a diagnosis and a less complete clinical picture should
also be considered for testing and will likely be identified with
genomic strategies, such as exome sequencing. This might
lead to an even greater range of TALDO-D phenotypes. We
suggest including TALDO-D in the differential diagnosis of
the following diseases: congenital infections: TORCH [acro-
nym for toxoplasmosis, other (T. pallidum, varicella-zoster
virus, parvovirus), rubella virus, cytomegalovirus, herpes sim-
plex virus]; galactosemia; neonatal hemochromatosis; tyrosi-
nemia type 1; respiratory chain defects; lysosomal storage
disorders affecting the liver, such as Niemann-Pick type C
disease; congenital disorders of glycosylation (CDG) or
hematological malignancies, for which a diagnosis cannot be
confirmed. TALDO-D could be considered in patients with
septal cardiac defects, cryptorchidism, microphallus, or hyper-
gonadotropic hypogonadism if other symptoms, such as liver
impairment and/or hepatomegaly, are present.
All TALDO-D patients had elevated levels of polyols (ery-
thritol, arabitol, ribitol, sedoheptitol, and perseitol) and C7
sugars (sedoheptulose, mannoheptulose, and sedoheptulose-
7P) in urine and/or plasma, although in older patients, erythritol
or arabitol can be within normal range. Liver transplantation
does not appear to change urine polyols,20 probably due to
extrahepatic production of polyols in other organs, such as
the kidneys. Elevation of polyols are also found in other
defects of the pentose phosphate pathway (PPP)—ribose-
5-phosphate isomerase deficiency, transketolase deficiency,
and sedoheptulokinase deficiency21—or in children with
chronic kidney disease.22 The diagnosis can therefore be
made by combined investigations of polyols and C7 sugars
in urine, polyols in plasma, or enzyme analysis on fibro-
blasts, lymphoblasts, or even fetal liver. Genetic analysis of
the TALDO1 gene can confirm this diagnosis and can be of
value for prenatal diagnoses and counseling of families. Pre-
natal diagnosis might also be possible by measuring polyols
and C7 sugars in amniotic fluid.18 In all patients (100%),
two deleterious TALDO alleles were detected, 94% of
patients were homozygous for a mutation in the TALDO1
gene. With exome/genome sequencing, molecular diagnosis
of TALDO-D will become more common. In case of a novel
unclassified variant, the diagnosis should be confirmed by
metabolite measurements in urine and enzymatic analysis in
patient fibroblasts or lymphoblasts, or by proving the patho-
genicity of the variant. After confirmation of the diagnosis,
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family screening should be performed in siblings using urine
or DNA analysis, even when they are asymptomatic. The
recommended diagnostic flowchart is shown in Figure 1.
4.3 | Genotype–phenotype correlation
There is no clear genotype–phenotype correlation, which is
hampered by the small number of affected individuals and small
number of mutations. In one family (F13), there was a variable
presentation among their three sibs: two presented around the
age of 7 months with hepatomegaly and developed liver cirrho-
sis; one of them also developed hepatocellular carcinoma. The
third sibling was asymptomatic at the age of 9 years. This fam-
ily was not known to be consanguineous. Some mutations could
be suggestive of late presentation (e.g., the c.512C > T;
p.Ser171Phe), or early presentation (e.g., c.512_514delCCT;
p.Ser171del), but this remains to be confirmed.
4.4 | Pathophysiological mechanisms
A defect of TALDO in the pentose phosphate pathway not
only has an effect on organogenesis but also on the function
of organ systems after birth. Transaldolase is an important
enzyme in the PPP, and its deficiency has been shown to
deplete NADPH, glutathione (GSH), and diminish nitric
oxide (NO) production, lead to decreased mitochondrial
transmembrane potential and mitochondrial mass and
reduced adenosine triphosphate/adenosine diphosphate
(ATP/ADP) ratio in the liver of TALDO1−/− mice.23 In
fibroblast and lymphoblast cell lines from a TALDO-D
patient, the nucleotides NADPH and NAD+ were also
depleted, while ADP-ribose had accumulated. A diminished
mitochondrial transmembrane potential was also present, but
there was an increased mitochondrial mass, which was asso-
ciated with increased NO, ATP, and Ca2+. Also, enhanced
apoptosis was detected.19 The differences found might be
related to difference in organ systems or between species.
Failure to recycle ribose-5P through the nonoxidative
branch, and conversion of C5 sugar phosphates to C5 sugars
to C5 polyols converting NADPH to NADH+ results in
decreased NADPH necessary for reductive biosynthesis
(such as lipid synthesis, cholesterol synthesis, and fatty acid
chain elongation) and leads to secondary depletion of GSH
and increased oxidative stress. It thus seems expected that
the liver (detoxification and synthesis) and bone marrow
(hematopoiesis) are the organs most affected. Oxidative
stress due to dysfunction of the PPP could account not only
for defects in organogenesis but also for chronic liver dis-
ease with fibrosis and cirrhosis, hepatocellular carcinoma,
and hematological abnormalities.
Accumulation of the potentially toxic sugar-phosphate
(sedoheptulose-7P) and/or polyols (erythritol, arabitol, ribi-
tol, sedoheptitol, perseitol) and C7 sugars (mannoheptulose
and sedoheptulose) might result in liver damage, as has been
FIGURE 1 Diagnostic flowchart
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shown in patients with galactosemia in whom galactose-1P
and galactitol accumulate. In a mouse model, Perl et al.
show that mitochondrial damage resulted in abnormal fertil-
ity in TAL−/− mice. Treatment with NAC improved gluta-
thione production and fertility in TAL−/+ mice, but failed to
improve fertility in TAL−/− mice.24
Demand for the PPP is highest in the liver, and the liver is
the organ with the highest enzyme activity next to the kid-
ney.25 Kidney involvement is also one of the most common
abnormalities in this patient cohort. Kidney problems reported
are mainly tubular dysfunction (high energy demand), where
loss of calcium is one of the main features (tubulopathy), pos-
sibly even leading to nephrocalcinosis or kidney stones.
Although symptoms occur in organs with the highest TALDO
enzyme activity, there seems to be no correlation between
residual enzymatic activity and clinical outcome.
4.5 | Treatment
To date there is no cure for TALDO-D, and therapy consists
of supportive symptomatic treatment: e.g., surgical correction
of cardiac abnormalities, supplementation in calcium and vita-
min D (when loss is due to tubular dysfunction, taking care to
prevent renal stones), and red blood cell and platelet transfu-
sions, when indicated. Preventive measures aim to control the
risk of increased bleeding and liver dysfunction, such as vita-
min K supplementation, and hormone replacement treatment
in hypergonadotropic hypogonadism to induce puberty.
Experimental therapies have used NAC—as suggested by
preclinical experiments, either alone or in combination with
other antioxidants—with limited success. The clinical signifi-
cance of normalized serum AFP in a patient treated with
NAC is uncertain, although it may reflect decreased hepato-
cyte injury and reduced hepatocarcinogenesis, as suggested in
the mouse disease model.23,26 A decrease of AFP was also
observed in most TALDO-D patients without NAC treat-
ment.27 Further treatment experiences are needed to determine
the role of these therapies in TALDO-D.
To date, etiology of hematological abnormalities remains
unclear but could be due to liver damage that leads to
splenomegaly and sequestration of platelets; decreased cell
production; oxidative damage due to limited NADPH; and
anemia due to chronic disease. Besides NAC, vitamins C
and E have been suggested12 as antioxidants. Ultimately,
liver transplantation should be considered in patients with
chronic progressive liver disease and promptly in neonates
with liver failure before the age of 6 months, as these
patients have shown the highest mortality rates.
4.6 | Markers for follow-up
We recommend following hematological parameters (blood
count, including reticulocyte, LDH, haptoglobin and
erythropoietin to better evaluate anemia), liver (clotting fac-
tors, transaminases, bilirubin, conjugated bilirubin, gamma-
glutamyl transpeptidase (GTP), alkaline phosphatase, and
kidney function (glomerular and tubular), and AFP for eval-
uation of liver carcinogenesis every 3–6 months. Regular
visceral imaging studies (US, computed tomography, mag-
netic resonance imaging) should be performed according to
local protocols for patients with chronic liver disease with
risk of cirrhosis.
Follow-up of height, weight, and puberty, including Tan-
ner staging, is important. Gonadal function should be
assessed based on clinical symptoms such as cryptorchidism,
microphallus, delayed puberty, or infertility. No abnormali-
ties were found in the hypothalamic–pituitary–adrenal axis,
so routine screening for these issues is not advocated. In our
cohort, one patient had primary hypothyroidism of unknown
etiology and one patient had subclinical hypothyroidism.
We advise low-threshold assessment of thyroid function.
The clinician should be aware that in some patients bone
mineral content is decreased and should be assessed using
dual-energy X-ray absorptiometry (DEXA) scans to monitor
the risk for developing osteopenia.
5 | CONCLUSIONS
TALDO-D is a rare metabolic disorder. By combining the
information of patients with TALDO-D, we have provided a
comprehensive clinical overview with comprehensive clini-
cal information, including endocrine symptoms and a broad
clinical phenotype.
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